Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Lorcaserin Stories

2014-04-14 12:34:04

SAN DIEGO, April 14, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to...

2014-04-14 12:27:47

Campaign Creates Awareness of Prescription Drug Option for Chronic Weight Management WOODCLIFF LAKE, N.J., April 14, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ(®) (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC. To view the multimedia assets associated with this release, please click:...

2014-02-27 16:28:46

- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time - SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. "The 2013 US commercial launch of BELVIQ®, global expansion of our collaboration with Eisai, and the advancement of our research and development programs have positioned Arena for an outstanding year in...

2014-02-24 08:28:05

Patient Recruitment and Enrollment Now Underway WOODCLIFF LAKE, N.J., Feb. 24, 2014 /PRNewswire/ -- Eisai Inc. today announced that patient recruitment and enrollment are currently underway for CAMELLIA-TIMI 61, a randomized double-blind, placebo-controlled outcomes trial to evaluate the effect of long-term treatment with lorcaserin HCl on the incidence of major adverse cardiovascular events and new onset type 2 diabetes mellitus in obese (BMI > 30 kg/m(2)) and overweight (BMI > 27...

2014-02-20 08:31:51

SAN DIEGO, Feb. 20, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and report fourth quarter and full year 2013 financial results after the NASDAQ Global Select Market closes on Thursday, February 27, 2014. That same day, Arena will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). The conference call may be accessed by dialing 877.643.7155 for domestic callers and...

2014-02-12 08:28:44

-- Eisai's Filing for Approval of BELVIQ as a Treatment for Chronic Weight Management Triggers $500,000 Milestone Payment to Arena -- SAN DIEGO, Feb. 12, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios Ltda., a subsidiary of Eisai Inc., has filed for marketing authorization of BELVIQ® as a treatment for chronic weight management with the Brazilian Health Surveillance Agency (Anvisa). In connection with the filing, Arena will receive a...

2014-02-10 08:26:31

-- BELVIQ Now Covered by CVS Caremark -- SAN DIEGO, Calif., Feb. 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai has secured improved patient access of BELVIQ(®) (lorcaserin HCl) with two leading healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exceeds 50 percent. CVS Caremark customers (employers and health plans) have broadened the coverage of...

2014-02-10 08:26:18

Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent WOODCLIFF LAKE, N.J., Feb. 10, 2014 /PRNewswire/ -- Eisai Inc. reported today that it has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit companies: CVS Caremark and Aetna. CVS Caremark customers (employers and health plans) have broadened the coverage of Eisai's BELVIQ, according to Fingertip Formulary, an integrated database of formulary...

2013-11-27 08:25:27

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 25(th) Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at The New York Palace Hotel in New York City. A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com....

2013-11-18 08:28:37

WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a new data analysis from the BELVIQ(®) (lorcaserin HCl) Phase 3 clinical trial program will be presented at the American Heart Association 2013 Scientific Sessions, November 16-20 in Dallas, Texas. The following abstract highlighting BELVIQ data will be presented: -- The Effects of Lorcaserin on High-Sensitivity C-reactive Protein in...